Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17
As a dual GIP/GLP-1 receptor agonist, tirzepatide works through two pathways rather than one, which clinical trials have shown produces greater average weight loss compared to semaglutide alone
Benefits of Activating GLP-1 Receptors By increasing endogenous GLP-1 or using agonists that mimic GLP-1, we can activate GLP-1 receptors and obtain therapeutic benefits such as the following: Weight Control and Improved Satiety GLP-1 slows digestion, suppresses appetite, and enhances metabolism to promote one to achieve optimal weight
Lower appetite
Unlike Zepbound, Mounjaros primary approval is for type 2 diabetes management, not specifically for weight loss
By improving glycemic control and reducing albuminuria, Semaglutide plays a crucial role in managing diabetic nephropathy
95% CI, 1.23 to 1.52) [39]
